PRESSING Need of Precision Care in HER2-Positive Colorectal Cancer: The ELEPHANT in the Room

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2023 Nov 17

PMID 37975903

Authors

Kanwal P S Raghav

Jonathan M Loree

Scott Kopetz

Affiliations

Soon will be listed here.

Abstract

Although dual HER2 inhibition has shown promising clinical activity in patients with RAS wild-type HER2-positive metastatic colorectal cancer, predictive biomarkers of response/resistance are less well characterized. Activating HER2/RTK/MAPK genomic alterations appears to blunt the clinical benefit of dual anti-HER2 therapy and may hold a potential albeit partial role in patient selection. See related article by Randon et al., p. 436.

References

Zuo W, Jiang Y, Wang Y, Xu X, Hu X, Liu G . Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer. Clin Cancer Res. 2016; 22(19):4859-4869. DOI: 10.1158/1078-0432.CCR-15-3036. View

Bose R, Kavuri S, Searleman A, Shen W, Shen D, Koboldt D . Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2012; 3(2):224-37. PMC: 3570596. DOI: 10.1158/2159-8290.CD-12-0349. View

Presley C, Tang D, Soulos P, Chiang A, Longtine J, Adelson K . Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting. JAMA. 2018; 320(5):469-477. PMC: 6142984. DOI: 10.1001/jama.2018.9824. View

Loree J, Bailey A, Johnson A, Yu Y, Wu W, Bristow C . Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. J Natl Cancer Inst. 2018; 110(12):1409-1417. PMC: 6292791. DOI: 10.1093/jnci/djy067. View

Randon G, Nakamura Y, Yaeger R, Lonardi S, Cremolini C, Elez E . Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study. Clin Cancer Res. 2023; 30(2):436-443. PMC: 10792357. DOI: 10.1158/1078-0432.CCR-23-1379. View

Hyman D, Piha-Paul S, Won H, Rodon J, Saura C, Shapiro G . HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018; 554(7691):189-194. PMC: 5808581. DOI: 10.1038/nature25475. View

Yoshino T, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H . Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nat Commun. 2023; 14(1):3332. PMC: 10247780. DOI: 10.1038/s41467-023-38032-4. View

Schubert L, Elliott A, Le A, Estrada-Bernal A, Doebele R, Lou E . family fusions are recurrent and actionable oncogenic targets across cancer types. Front Oncol. 2023; 13:1115405. PMC: 10164992. DOI: 10.3389/fonc.2023.1115405. View

Guan Y, Wang Y, Li H, Meng J, You X, Zhu X . Molecular and clinicopathological characteristics of gene fusions in 32,131 Chinese patients with solid tumors. Front Oncol. 2022; 12:986674. PMC: 9582139. DOI: 10.3389/fonc.2022.986674. View

10.

Nakamura Y, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y . Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nat Med. 2021; 27(11):1899-1903. PMC: 8604726. DOI: 10.1038/s41591-021-01553-w. View

11.

Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F . Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016; 17(6):738-746. DOI: 10.1016/S1470-2045(16)00150-9. View

12.

Greulich H, Kaplan B, Mertins P, Chen T, Tanaka K, Yun C . Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A. 2012; 109(36):14476-81. PMC: 3437859. DOI: 10.1073/pnas.1203201109. View

13.

Conlon N, Kooijman J, van Gerwen S, Mulder W, Zaman G, Diala I . Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors. Br J Cancer. 2021; 124(7):1249-1259. PMC: 8007737. DOI: 10.1038/s41416-020-01257-x. View

14.

Hechtman J, Zehir A, Yaeger R, Wang L, Middha S, Zheng T . Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. Mol Cancer Res. 2015; 14(3):296-301. PMC: 4972456. DOI: 10.1158/1541-7786.MCR-15-0392-T. View

15.

Kavuri S, Jain N, Galimi F, Cottino F, Leto S, Migliardi G . HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov. 2015; 5(8):832-41. PMC: 4527087. DOI: 10.1158/2159-8290.CD-14-1211. View

16.

West H . No Solid Evidence, Only Hollow Argument for Universal Tumor Sequencing: Show Me the Data. JAMA Oncol. 2016; 2(6):717-8. DOI: 10.1001/jamaoncol.2016.0075. View

17.

Elemento O, Leslie C, Lundin J, Tourassi G . Artificial intelligence in cancer research, diagnosis and therapy. Nat Rev Cancer. 2021; 21(12):747-752. DOI: 10.1038/s41568-021-00399-1. View

18.

Siravegna G, Sartore-Bianchi A, Nagy R, Raghav K, Odegaard J, Lanman R . Plasma HER2 () Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer. Clin Cancer Res. 2019; 25(10):3046-3053. DOI: 10.1158/1078-0432.CCR-18-3389. View

19.

Meric-Bernstam F, Hurwitz H, Raghav K, McWilliams R, Fakih M, VanderWalde A . Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019; 20(4):518-530. PMC: 6781620. DOI: 10.1016/S1470-2045(18)30904-5. View